Compare e l f Beauty Inc (ELF) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company shows robust revenue growth, expanding internationally with the rhode brand launch in Europe via Sephora, though net margins are thin at 3.38%. Valuation ratios are elevated with a P/E of 108.12, reflecting high growth expectations. Analyst consensus is mixed with a 48.27% buy rating but a price target of $95.91 below the current price.

Outlook: ELF's aggressive marketing and global expansion present growth opportunities, but the stock's premium valuation and high P/E pose risks if growth slows. Investor sentiment is cautiously optimistic, supported by institutional buying, yet overbought RSI levels suggest near-term volatility. Key risks include execution of international strategy and competitive pressures in the beauty sector.

Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.

Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.